Molnupiravir (MK-4482)

Influenza, Covid 19
Patent oppositions filed in
Argentina, Brazil, India, and Russian Federation

An investigational oral antiviral drug for use in the treatment of Covid 19 infection. Initially developed for use in the treatment of influenza.

This drug is missing the following documents, can you help us by contributing something?


Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

CountryDateWho FiledOpposition typeOpposition statusPatent typeRelated patent applicationMore info
India09-03-2021Prathiba Sivasubramanian Pre-GrantUnder ExaminationCompositions201717025098View/Comment
India22-03-2021Cancer Patient Aid Association (CPAA)Pre-GrantUnder ExaminationCompositions201717025098View/Comment
India31-03-2021Entrepreneurship Development CenterPre-GrantUnder ExaminationCompositions201717025098View/Comment
India29-04-2021Keelu LakshminarayanaPre-GrantUnder ExaminationMolecules202017019418View/Comment
Russian Federation14-03-2022ITPC-EECAPre-GrantUnder ExaminationMoleculesEA202091005View/Comment
Brazil14-06-2022ABIA/GTPIPre-GrantUnder ExaminationMoleculesBR122021012627-5View/Comment
Argentina22-06-2022Fundación Grupo Efecto PositivoPre-GrantUnder ExaminationMoleculesAR12285A1View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top